Mural Oncology plc Cash Flow Conversion Efficiency
Mural Oncology plc cash flow conversion efficiency. Based on the latest financial reports, Mural Oncology plc (MURA) has a cash flow conversion efficiency ratio of -0.335x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($55.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mural Oncology plc (2021–2024)
Cash flow conversion efficiency of Mural Oncology plc from 2021 to 2024. This chart illustrates how Mural Oncology plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Mural Oncology plc for real-time trading data and today's change.
Mural Oncology plc Cash Flow Conversion Ratio Explained
Mural Oncology plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mural Oncology plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mural Oncology plc ranked by their cash flow conversion efficiency. Also see Mural Oncology plc (MURA) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FIT INVEST JSC
VN:FIT
|
-0.020x |
|
Fundamental Global Inc.
NASDAQ:FGNX
|
-0.010x |
|
RATH Aktiengesellschaft
VI:RAT
|
0.046x |
|
Parlem Telecom Companyia de Telecomunicacions S.A.
MC:PAR
|
0.753x |
|
Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS
IS:PKART
|
0.157x |
|
Minetech Resources Bhd
KLSE:7219
|
0.075x |
|
GSE Co. Ltd
KQ:053050
|
0.013x |
|
Drax Group PLC
LSE:DRX
|
0.003x |
Annual Cash Flow Conversion Efficiency for Mural Oncology plc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Mural Oncology plc from 2021 to 2024. Review MURA financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $140.50 Million | $-128.54 Million | -0.915x | -24.26% |
| 2023-12-31 | $263.82 Million | $-194.25 Million | -0.736x | -109.46% |
| 2022-12-31 | $-21.66 Million | $-168.59 Million | 7.785x | -11.16% |
| 2021-12-31 | $-17.88 Million | $-156.67 Million | 8.763x | -- |
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more